Core Viewpoint - Meituan expects to incur a loss of approximately RMB 23.3 billion to RMB 24.3 billion in the fiscal year 2025, contrasting with a profit of approximately RMB 35.8 billion in 2024 [1] Financial Performance - The anticipated loss for 2025 is primarily due to the core local commerce segment shifting from an operating profit of approximately RMB 52.4 billion in 2024 to an operating loss of approximately RMB 6.8 billion to RMB 7 billion in 2025 [1] - The company is increasing its investment in overseas operations to enhance its competitive position [1] Strategic Initiatives - To address unprecedented competition in 2025, the company has strategically increased investments across its entire ecosystem to strengthen core advantages and promote sustainable growth [1]

Core Viewpoint - Kingworld Medicines Group (01110) expects a significant decline in profit for the first half of 2025, projecting a year-on-year decrease of approximately 70% to 75% compared to a profit of 45.6 million yuan in the first half of 2024 [1] Financial Performance - The company anticipates a loss attributable to shareholders of approximately 4.5 million yuan for the first half of 2025, while projecting a profit attributable to shareholders of about 30.7 million yuan for the first half of 2024 [1] Business Operations - The board attributes the decrease in profit primarily to a reduction in gross profit of approximately 50% to 55% from its Chinese distribution business for imported pharmaceutical and health products, which is due to a slowdown in market demand for these products [1] - This decline in gross profit is partially offset by an increase in gross profit of about 10% to 15% from Shenzhen Dongdixin Technology Co., Ltd [1]